55,795 Shares in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Acquired by SteelPeak Wealth LLC

SteelPeak Wealth LLC acquired a new stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 55,795 shares of the company's stock, valued at approximately $1,617,000. SteelPeak Wealth LLC owned about 0.12% of Amphastar Pharmaceuticals at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Boston Trust Walden Corp increased its holdings in shares of Amphastar Pharmaceuticals by 24.2% in the first quarter. Boston Trust Walden Corp now owns 1,215,624 shares of the company's stock valued at $35,241,000 after purchasing an additional 236,704 shares during the period. Dimensional Fund Advisors LP increased its holdings in shares of Amphastar Pharmaceuticals by 9.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,198,590 shares of the company's stock valued at $44,503,000 after purchasing an additional 105,288 shares during the period. Northern Trust Corp increased its holdings in shares of Amphastar Pharmaceuticals by 5.1% in the fourth quarter. Northern Trust Corp now owns 613,170 shares of the company's stock valued at $22,767,000 after purchasing an additional 29,808 shares during the period. Marshall Wace LLP increased its holdings in shares of Amphastar Pharmaceuticals by 7.1% in the fourth quarter. Marshall Wace LLP now owns 608,706 shares of the company's stock valued at $22,601,000 after purchasing an additional 40,212 shares during the period. Finally, Renaissance Technologies LLC increased its holdings in shares of Amphastar Pharmaceuticals by 7.4% in the fourth quarter. Renaissance Technologies LLC now owns 525,500 shares of the company's stock valued at $19,512,000 after purchasing an additional 36,100 shares during the period. Hedge funds and other institutional investors own 65.09% of the company's stock.

Amphastar Pharmaceuticals Trading Down 2.5%

Shares of AMPH stock opened at $21.66 on Friday. The company has a quick ratio of 2.02, a current ratio of 2.95 and a debt-to-equity ratio of 0.80. The stock has a market cap of $1.02 billion, a P/E ratio of 7.85, a P/E/G ratio of 5.78 and a beta of 0.72. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $21.48 and a fifty-two week high of $53.96. The business has a fifty day simple moving average of $24.53 and a 200-day simple moving average of $28.35.

Analyst Ratings Changes

A number of research analysts have recently issued reports on AMPH shares. Needham & Company LLC reiterated a "hold" rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, April 10th. Wells Fargo & Company cut their price objective on Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating for the company in a research report on Thursday, May 8th. Piper Sandler cut their price objective on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating for the company in a research report on Friday, March 21st. Finally, JPMorgan Chase & Co. reiterated a "neutral" rating and issued a $30.00 price objective (down previously from $45.00) on shares of Amphastar Pharmaceuticals in a research report on Monday, May 12th. Four research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $32.33.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.

Want to see what other hedge funds are holding AMPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.